Coastline Trust Co Invests $205,000 in AstraZeneca plc (AZN) Stock

Coastline Trust Co purchased a new position in AstraZeneca plc (NYSE:AZN) in the first quarter, HoldingsChannel.com reports. The fund purchased 5,075 shares of the company’s stock, valued at approximately $205,000.

A number of other large investors have also recently bought and sold shares of AZN. Bank of New York Mellon Corp grew its stake in AstraZeneca by 5.9% in the third quarter. Bank of New York Mellon Corp now owns 188,336 shares of the company’s stock worth $7,452,000 after purchasing an additional 10,560 shares in the last quarter. Credit Suisse AG boosted its stake in AstraZeneca by 73.9% in the third quarter. Credit Suisse AG now owns 18,873 shares of the company’s stock valued at $746,000 after acquiring an additional 8,023 shares during the period. Jane Street Group LLC boosted its stake in AstraZeneca by 278.6% in the third quarter. Jane Street Group LLC now owns 16,490 shares of the company’s stock valued at $653,000 after acquiring an additional 12,135 shares during the period. Mackenzie Financial Corp boosted its stake in AstraZeneca by 8.2% in the third quarter. Mackenzie Financial Corp now owns 29,680 shares of the company’s stock valued at $1,174,000 after acquiring an additional 2,247 shares during the period. Finally, Neuberger Berman Group LLC boosted its stake in AstraZeneca by 174.2% in the third quarter. Neuberger Berman Group LLC now owns 527,906 shares of the company’s stock valued at $20,890,000 after acquiring an additional 335,355 shares during the period. Institutional investors and hedge funds own 18.32% of the company’s stock.

Shares of NYSE:AZN opened at $37.99 on Monday. AstraZeneca plc has a 12 month low of $34.38 and a 12 month high of $43.29. The company has a market cap of $96.22 billion, a P/E ratio of 10.98, a PEG ratio of 1.16 and a beta of 0.51. The company has a current ratio of 0.96, a quick ratio of 0.78 and a debt-to-equity ratio of 1.24.

AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, April 26th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.02. The firm had revenue of $5.47 billion for the quarter, compared to analysts’ expectations of $5.40 billion. AstraZeneca had a return on equity of 32.47% and a net margin of 9.76%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.48 earnings per share. As a group, analysts anticipate that AstraZeneca plc will post 1.78 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on AZN shares. Cowen raised AstraZeneca from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $42.00 to $48.00 in a report on Monday, April 1st. ValuEngine cut AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, April 1st. UBS Group cut AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 price target on the stock. in a report on Tuesday, April 2nd. Goldman Sachs Group reaffirmed a “sell” rating on shares of AstraZeneca in a report on Tuesday, February 26th. Finally, Zacks Investment Research cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. AstraZeneca currently has an average rating of “Hold” and a consensus target price of $45.29.

ILLEGAL ACTIVITY WARNING: “Coastline Trust Co Invests $205,000 in AstraZeneca plc (AZN) Stock” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2019/04/29/coastline-trust-co-invests-205000-in-astrazeneca-plc-azn-stock.html.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: NASDAQ

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.